Compare Adaptive Biotechnologies Corp (ADPT) vs Iron Mountain Inc (IRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Iron Mountain Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while Iron Mountain Inc trades at $114.67 (market cap $34.44B). The key difference: Iron Mountain Inc is far larger — about 10.3× Adaptive Biotechnologies Corp's market cap, and Iron Mountain Inc pays a 2.99% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | IRM | |
|---|---|---|
Market Cap | $3.33B | $34.44B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $133.06 |
52-Week Low | $10.24 | $78.86 |
Enterprise Value | $3.19B | $53.57B |
Dividend Yield | — | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Iron Mountain (IRM) trades at $115.75, down 1.2% on the day, with strong recent earnings beats and a bullish analyst consensus of $138.67 price target. The stock shows technical bearish signals despite positive momentum news, while fundamentals reveal modest revenue growth to $6.90B in 2025 but declining net margins to 3.76%. Recent debt offerings of $1.5B highlight capital strategy moves amid high leverage.
Outlook remains cautiously optimistic given earnings outperformance and industry tailwinds, but risks include elevated debt levels and margin pressure. The stock offers growth potential with a 65% buy rating from analysts, though investors should weigh technical weakness against fundamental resilience in the information services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
